Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience

Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008;103:1283–97.

Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–46.

van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.

Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:923–30.

Narahari S, Juwle A, Basak S, Saranath D. Prevalence and geographic distribution of hepatitis C virus genotypes in Indian patient cohort. Infect Genet Evol. 2009;9:643–5.

Puri P, Anand AC, Saraswat VA, et al. Consensus statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL recommendations for management of HCV in India. J Clin Exp Hepatol. 2014;4:117–40.

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.

Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–35.

Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull. 2015;113:31–44.

Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312:631–40.

Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308.

Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA. Inhibitors of the hepatitis C virus polymerase: mode of action and resistance. Viruses. 2015;7:5206–24.

EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–95.

AASLD. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org . Accessed 7 March 2017.

Puri P, Anand AC, Saraswat VA, et al. Consensus statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: status report of HCV infection in India. J Clin Exp Hepatol. 2014;4:106–16.

Puri P, Anand AC, Saraswat VA, et al. Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection in 2015. J Clin Exp Hepatol. 2015;5:221–38.

Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepat. 2015;22(Suppl 1):1–5.

Sood A, Midha V, Sood N, Bansal M. Antiviral treatment for chronic hepatitis C: reasons for non-treatment in a northern Indian center. Indian J Gastroenterol. 2006;25:319–20.

Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20:669–77.

Alonso S, Riveiro-Barciela M, Fernandez I, et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat. 2017;24:304–11.

Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–92.

Buti M, Llaneras J, Riveiro-Barciela M, Esteban R. Therapy for hepatitis C genotype 3: moving forward. J Viral Hepat. 2015;22:683–90.

Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149:1462–70.

Sood A, Midha V, Mahajan R, et al. Results of sofosbuvir based combination therapy for chronic hepatitis C cohort of Indian patients in real life clinical practice. J Gastroenterol Hepatol. 2017; 32: 894-900.

Shah SR, Chowdhury A, Mehta R, et al. Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India. J Viral Hepat. 2017;24:371–9.

Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. J Gastroenterol Hepatol. 2017;32:859–63.

Mehta R, Kabrawala M, Nandwani S, et al. Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in “real-life” cohort. Indian J Gastroenterol. 2016;35:459–64.

European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.

Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–35.

Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–70.

Hezode C, Lebray P, De Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int. 2017; doi: 10.1111/liv.13383 .

Herzer K, Welzel TM, Spengler U, et al. Real-world experience with daclatasvir plus sofosbuvir +/− ribavirin for post-liver transplant HCV recurrence and severe liver disease. Transpl Int. 2017;30:243–55.